Efudex contains the active ingredient fluorouracil and is marketed as a topical cream in 1 % and 5 % strengths. It belongs to the skin-care and oncology-support therapeutic class, used primarily for the treatment of precancerous skin lesions and certain superficial skin cancers. In Hong Kong, Efudex is a prescription-only medication regulated by the Department of Health.
Fluorouracil is a antimetabolite that interferes with DNA synthesis. When applied to the skin, the drug penetrates the epidermis and is converted into active metabolites that:
These actions selectively affect rapidly dividing keratinocytes-cells that are over-active in actinic keratoses and superficial basal-cell carcinomas-leading to cellular death and lesion resolution. The topical formulation delivers the drug directly to the target area, minimizing systemic exposure.
These indications are approved by the Hong Kong Department of Health for the 5 % strength; the 1 % formulation is often chosen for patients with a lower tolerance to inflammation.
If patients are taking other medications, they should inform their healthcare provider before starting Efudex.
Application tips
Missed dose - Apply the missed dose as soon as remembered, unless it is close to the time of the next scheduled dose; do not double the dose.
Overdose - Excessive application over large skin areas may increase systemic absorption. Signs include nausea, vomiting, or unexpected fatigue. Seek urgent medical care; supportive measures are the primary treatment.
Discontinuation - Therapy may be stopped once the lesion has resolved or if severe irritation develops. No tapering is required, but patients should continue to protect the area from sun exposure.
This article provides educational information about Efudex and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
The inflammatory response commonly peaks between days 7-14 and may persist for 2-4 weeks, gradually resolving as the treated lesion heals.
Yes, Efudex is frequently used on facial actinic keratoses. The skin on the face is more delicate, so many clinicians start with the 1 % strength to minimize severe irritation.
Gentle cleaning with mild soap and water, followed by a moisturizing ointment (e.g., petroleum jelly) can soothe crusting. If ulceration becomes painful or expands, seek medical evaluation.
Concurrent use of topical corticosteroids can reduce inflammation but may also diminish Efudex’s effectiveness. Always discuss combination therapy with a dermatologist.
Topical fluorouracil is not typically screened for in standard workplace drug tests and is unlikely to result in a positive finding.
Large-area application increases the risk of systemic absorption. When extensive treatment is needed, a physician may opt for lower-strength formulations or limit the treated surface area.
Symptoms include unexplained fever, mouth sores, persistent nausea, or unusual bruising. These require prompt medical assessment.
Keep the tube tightly capped at room temperature, away from heat and humidity. Discard any cream that changes color or develops an odd odor.
Yes-protecting the treated skin from UV exposure helps reduce irritation and supports healing. Use a broad-spectrum sunscreen after the cream has dried.
Patients prone to abnormal scar formation should discuss the risk with their dermatologist, as intense inflammation may exacerbate keloid development.
